Kidney Diseases Associated With Inflammatory Bowel Disease: Impact of Chronic Histologic Damage, Treatments, and Outcomes

Other authors

Institut Català de la Salut

[Yandian F] Department of Nephrology, Hospital de Clínicas “Dr. Manuel Quintela”, Montevideo, Uruguay. [Caravaca-Fontán F] Department of Nephrology, Instituto de Investigación Hospital “12 de Octubre” (imas12), Madrid, Spain. [Herrera Hernandez LP, Sethi S] Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. [Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fervenza FC] Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA

Vall d'Hebron Barcelona Hospital Campus

Publication date

2024-02-14T12:28:25Z

2024-02-14T12:28:25Z

2024-02



Abstract

Inflammatory bowel disease; Interstitial nephritis; Kidney failure


Enfermedad inflamatoria intestinal; Nefritis intersticial; Insuficiencia renal


Malaltia inflamatòria intestinal; Nefritis intersticial; Insuficiència renal


Introduction Kidney disease is a well-known extraintestinal manifestation (EIM) associated with inflammatory bowel disease (IBD), with a variety of underlying etiologies. However, little is known about the overall outcomes and predictors. Methods This is a retrospective, observational cohort study. Patients with IBD in whom a native kidney biopsy was performed at Mayo Clinic (Rochester, MN) between 1994 and 2022, were included. Demographic, clinical, and histologic characteristics of prognostic interest were collected. The main outcomes were kidney failure, disease remission, kidney function changes at last follow-up, and death. Results From a total cohort of 318 patients, we selected a study group of 111 patients followed-up with at our institution (45 ulcerative colitis [UC] and 66 Crohn’s disease [CD]), with a mean age of 48 ± 17 years (40% females). IgA nephropathy (IgAN), chronic interstitial nephritis (CIN), and acute interstitial nephritis (AIN) were the most common diagnoses (22%, 19%, 13%, respectively). Median estimated glomerular filtration rate (eGFR) at presentation was 30 ml/min per 1.73 m2 (interquartile range [IQR]: 17–54) and urinary protein-to-creatinine ratio [UPCR] 0.8 g/g (0.3–3.4), without differences between IBD types. During a median follow-up of 59 months (12–109), 29 patients (26%) reached kidney failure. By multivariable analysis, the main predictors of kidney failure were age (hazard ratio [HR]: 1.04; P = 0.002), baseline eGFR (HR: 0.94; P = 0.003) and histologic chronicity score (HR: 4.01; P < 0.001). Therapeutic management varied according to underlying etiology. Global survival (kidney failure + death) was significantly better in patients who achieved complete or partial remission, or stabilization or improvement of kidney function. Conclusion One-fourth of patients with IBD with kidney disease may reach kidney failure, and the main determinants of this outcome is age, baseline eGFR, and degree of chronicity in kidney biopsy.

Document Type

Article


Published version

Language

English

Publisher

Elsevier

Related items

Kidney International Reports;9(2)

https://doi.org/10.1016/j.ekir.2023.11.011

Recommended citation

This citation was generated automatically.

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International

http://creativecommons.org/licenses/by-nc-nd/4.0/

This item appears in the following Collection(s)